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P
roliferative diabetic retinopathy
(PDR) remains the leading cause of
blindness among working-age indi-
viduals in developed countries (1). Dia-
betic macular edema (DME), another
important event that occurs in diabetic
retinopathy, is more frequent in type 2
than type 1 diabetes (2). Whereas PDR is
the most common sight-threatening le-
sion in type 1 diabetes, DME is the pri-
mary cause of poor visual acuity in type 2
diabetes. Because of the high prevalence
of type 2 diabetes, DME is the main cause
of visual impairment for diabetic patients
(2). In addition, DME is almost invariably
present when PDR is detected in type 2
diabetes (3). Neovascularization caused
by severe hypoxia is the hallmark of PDR,
whereas vascular leakage caused by the
breakdown of the blood retinal barrier
(BRB) is the main event involved in the
pathogenesis of DME (4,5).
STANDARD TREATMENT—
Although tight control of both blood glu-
cose levels and hypertension is essential
topreventorarrestprogressionofthedis-
ease, the recommended goals are difﬁcult
to achieve in many patients and, conse-
quently, diabetic retinopathy develops
duringtheevolutionofthedisease.When
PDR or clinically signiﬁcant DME do ap-
pear,argon-laserphotocoagulationiscur-
rently indicated, which the efﬁcacy of has
been widely demonstrated (6). However,
the optimal period for laser treatment has
frequently passed; moreover, it is not
uniformly successful in halting visual de-
cline. In addition, argon-laser photocoag-
ulation is associated with moderate visual
loss, some diminished visual ﬁeld, re-
duced color vision, and reduced contrast
sensitivity. The presence of these symp-
toms led to the prevailing thinking that
laser treatment prevents vision loss but
rarely results in visual improvement.
Intravitreal corticosteroids have been
successfully used in the eyes of patients
with persistent DME and loss of vision
following the failure of conventional
treatment (i.e., focal laser treatment and
attention to systemic risk factors). How-
ever, reinjections are commonly needed,
and there are substantial adverse effects
such as infection, glaucoma, and cataract
formation (6). In addition, recent reports
have shown that focal/grid photocoagula-
tion is more effective and has fewer side
effects than intravitreal triamcinolone for
DME (7,8).
Vitreoretinal surgery is an expensive
andcomplicatedtreatmentthatshouldbe
carried out only by vitreoretinal special-
ists experienced in this procedure, and it
is normally reserved for the ultimately
blinding complications of PDR, such as
severe vitreous hemorrhage and second-
aryretinaldetachment.Forthesereasons,
new pharmacological treatments based
on the understanding of the pathophysi-
ological mechanisms of diabetic retinop-
athy are needed.
The paucity of relevant clinical stud-
ies addressed to testing new drugs in dia-
betic retinopathy is due, in part, to the
necessity of long-term studies performed
in large cohorts of diabetic patients by
means of standardized masked grading of
retinal photographs. Although there is no
ﬁxedrule,thedurationofthetrialmustbe
consistent with the natural history of dia-
betic retinopathy and, consequently, at
least5yearsseemstobenecessaryforsep-
arating the behavior of retinopathy in the
intervention and control groups. In addi-
tion, most clinical trials have been aimed
at evaluating the progression of diabetic
retinopathy, whereas there have been few
studies targeting prevention. All these
caveats should be kept in mind when an-
alyzing clinical trials on diabetic retinop-
athy because they can signiﬁcantly
contribute to false-negative results. The
presence of diabetic retinopathy in non-
diabetic subjects is another challenge.
Wong et al. (9), in a study that included
morethan11,000participantsfromthree
population cohorts, provide evidence
that with the current fasting plasma glu-
cosecutoffof7.0mmol/lusedtodiagnose
diabetes, 7.4–13.4% of nondiabetic pa-
tients had diabetic retinopathy. This ﬁnd-
ing, apart from questioning the current
diagnostic criteria of diabetes, suggests a
potential limit to the risk reduction for
diabetic retinopathy that should be taken
into consideration when interpreting the
results of clinical trials.
Recently, two pivotal studies have
been published regarding the beneﬁcial
effects of two types of drugs (fenoﬁbrate
and candesartan) on diabetic retinopathy
(10–12). These studies fulﬁll all the main
requirements for obtaining a valid result:
long-term follow-up (5 years), a large
cohort of diabetic patients, retinopathy
assessed by standardized methods, and a
signiﬁcantnumberofpatientswithoutdi-
abetic retinopathy at study entry, thus al-
lowing evaluation of the effectiveness of
prevention.Inadvancedstagesofdiabetic
retinopathy, intravitreous anti–vascular
endothelial growth factor (VEGF) agents
have emerged as new treatments. These
drugs are yet to be approved for diabetic
retinopathy treatment, but they are cur-
rently used by ophthalmologists in se-
lected cases of PDR and DME (13,14).
This article discusses the current state of
knowledge concerning these novelties in
the medical treatment of diabetic retinop-
athy and highlight areas where further
studies and evidence are required.
FENOFIBRATE— Fenoﬁbrate is a
peroxisome proliferactor–activated re-
ceptor (PPAR)- agonist indicated for the
treatment of hypertriglyceridemia and
mixed dislipidemia. Its main action is to
lower plasma triglyceride levels, but it
also reduces total and LDL cholesterol,
raises HDL cholesterol, and decreases
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particles and apolipoprotein B (15). Re-
cently, Keech et al. (10) have reported re-
sults concerning laser treatment for
diabetic retinopathy from the FIELD (Fe-
noﬁbrate Intervention and Event Lower-
ing in Diabetes) study. The main aim of
thisrandomizedcontrolledtrialwastoas-
sess whether long-term lipid-lowering
therapy using fenoﬁbrate (a PPAR- ago-
nist)couldreducetheneedforlasertreat-
mentinalargecohort(n9,795)oftype
2diabeticpatients.Theaveragefollow-up
was 5 years, and the end point was the
need for laser treatment (a tertiary end
point of the main study). In an intention-
to-treat analysis, fenoﬁbrate (200 mg
oncedaily)reducedthefrequencyoflaser
treatment for macular edema by 31% and
for proliferative retinopathy by 30%. In
addition, in a substudy performed on pa-
tients in whom retinal status was graded
by fundus photography, fenoﬁbrate was
able to reduce the progression of existing
retinopathy. Although this study has
some limiting factors (16,17), the sub-
stantial beneﬁts obtained from reducing
theneedforlasertreatmentargueforcon-
sideration of using fenoﬁbrate in the
management of diabetic retinopathy.
However, our poor knowledge of the
mechanisms involved in its beneﬁcial ef-
fects in diabetic retinopathy might limit
its potential impact on clinical practice.
Theoretically,anotherPPAR-apartfrom
fenoﬁbrate can also be beneﬁcial for dia-
betic retinopathy; however, at present
this has been only demonstrated with
fenoﬁbrate.
The rationale for FIELD was that ele-
vated lipid levels in systemic circulation
constitute a risk factor for diabetic reti-
nopathy; therefore, long-term lipid-
lowering therapy with fenoﬁbrate could
reduce the progression of diabetic reti-
nopathy and the need for laser treatment
inpatientswithtype2diabetes.However,
no relationship between serum lipids and
the appearance or progression of diabetic
retinopathywasdetected.Thisisinagree-
ment with other prospective studies
showingthatserumlipidsareunrelatedto
the progression of diabetic retinopathy or
thedevelopmentofPDR(18,19).Inaddi-
tion, the Collaborative Atorvastatin Dia-
betes Study (CARDS), a randomized
controlled trial of 2,830 patients with
type 2 diabetes, did not ﬁnd atorvastatin
to be effective in reducing diabetic reti-
nopathy progression (20). However, this
study was limited by substantial missing
data (only 65% of patients had retinopa-
thy status recorded at baseline) and lack
of photographic grading for diabetic reti-
nopathy. Another randomized trial, the
ACCORD-EYE study that is now in
progress, could shed light on this issue
(21).Inthisstudy,theeffectsoflipidcon-
trol (statin vs. fenoﬁbrate added to a sta-
tin) on the progression of diabetic
retinopathy will be evaluated. There will
be 4,065 participants recruited to the
study at baseline for whom fundus pho-
tographswillbetakenwithin4monthsof
randomizationandagain4yearslater.Al-
though in the FIELD study there was
no relationship between the quantitative
levels of serum lipids and diabetic retin-
opathy, it is unknown whether the effec-
tiveness of fenoﬁbrate in modulating the
qualitativepropertiesoflipoproteins(i.e.,
reducing remnants and small dense LDL
particles) can contribute to its beneﬁcial
effects. In addition, it should be noted
that the mechanisms regulating intra-
retinal lipid transport rather than serum
levels might be more important in the
pathogenesis of diabetic retinopathy. In
this regard, we have recently shown that
apolipoprotein A1 (apo-A1) is overex-
pressed in the retina of diabetic patients
(22). Apo-A1 is a key factor for the in-
traretinal transport of lipids, thus pre-
venting lipid deposition and lipotoxicity,
anditisalsoapotentscavengerofreactive
oxygen species. Therefore, apo-A1 could
play an important role in protecting the
retina from oxidative stress. These ﬁnd-
ings have led us to hypothesize that the
retinas from diabetic patients have a
higher content of apo-A1 as a protective
mechanism; consequently, patients with
less capacity for apo-A1 production by
the retina will be more prone to develop
lipid deposition (hard exudates) and ret-
inal damage induced by oxidative stress.
Fenoﬁbric acid was shown to enhance
transcription of the gene of apo-A1 in the
liver (23), macrophages, and ﬁbroblasts
(24), but whether this is also true at the
retinal level remains to be elucidated.
Other nonlipidic mechanisms by
which fenoﬁbrate could be effective in
preventing or arresting diabetic retinopa-
thy might be the following:
1) PPAR- is present in endothelial cells
(25), and its activation by means of
PPAR- agonists has recently been
shown to inhibit expression of VEGF
receptor 2 (VEGFR2) and neovascu-
larization in human umbilical endo-
thelial cells (26). Varet et al. (27) have
demonstrated that fenoﬁbrate inhibits
angiogenesis in vitro and in vivo as
well as basic ﬁbroblast growth factor–
induced angiogenesis in vivo. In addi-
tion, in cells derived from human
ovarian cancer, cloﬁbric acid (a
PPAR-agonist)downregulatesVEGF
expression (28). Apart from its anti-
proliferative effects, fenoﬁbrate inhib-
its the apoptosis induced by high
glucose concentrations in human um-
bilical endothelial cells (29). More-
over, it has been demonstrated that
fenoﬁbrate prevents the apoptosis of
human retinal endothelial cells in-
ducedbyserumdeprivationthrougha
PPAR-–independent but AMP-
activated protein kinase–dependent
pathway (30). This activation of the
AMP-activated protein kinase path-
way in endothelial cells could lead to
an increase in endothelial nitric oxide
synthase phosphorylation and nitric
oxide production, thus resulting in
beneﬁcial effects on endothelial func-
tion (31).
2) PPAR- is associated with anti-
inﬂammatory and antioxidant activity
(32).IthasbeenreportedthatPPAR-
activation induces the expression and
activation of antioxidant enzymes,
suchassuperoxidedismutaseandglu-
tation peroxidase (33), and that acti-
vationofPPAR-inducesapoptosisof
human monocyte–derived macro-
phages (34). In addition, PPAR- ac-
tivators inhibit the expression of
vascular cell adhesion molecules on
the endothelium (35). This effect
might be useful in preventing leuko-
stasis (the inappropriate adherence of
leukocytes to the endothelium),
which is essential in the pathogenesis
of PDR.
3) PPAR- activation also has a neuro-
protective effect (33,36). This could
be important in preventing neuroreti-
nal degeneration, an early and crucial
event that occurs in diabetic retinopa-
thyevenbeforevascularabnormalities
can be detected (37).
4) The breakdown of the BRB, caused by
the disruption of tight junctions and
subsequent leakage, is the main factor
accounting for DME (6). Because of
the notable effect of fenoﬁbrate in pre-
venting DME progression, it would be
worthwhile to explore whether fenoﬁ-
brate is able to reduce the increased
permeability that exists in diabetic
retinopathy.
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fectsoffenoﬁbrateinalltheseareaswillbe
essential for understanding its beneﬁcial
effects in diabetic retinopathy, and it will
also be critical for using this drug as an
adjunct in the management of diabetic
retinopathy.
BLOCKING THE RENIN-
ANGIOTENSIN SYSTEM — Obser-
vational and clinical trials have shown
that blood pressure is an important mod-
iﬁable risk factor for diabetic retinopathy
and that lowering high blood pressure
signiﬁcantly reduces the development
and progression of retinopathy in both
type 1 and type 2 diabetic patients
(38,39). The blockade of the renin-
angiotensinsystem(RAS)withanACEin-
hibitor or by using angiotensin II type 1–
receptor (AT1-R) blockers is one of the
most used strategies for hypertension
treatment in diabetic patients. Apart from
the kidney, the RAS system is expressed
intheeye(40).Inaddition,thereisgrow-
ingevidencethatRASactivationintheeye
plays an important role in the patho-
genesis of diabetic retinopathy (40).
Therefore, apart from lowering blood
pressure, the blockade of the RAS could
also be beneﬁcial per se in reducing the
development and progression of diabetic
retinopathy.
The major components of RAS have
been identiﬁed in ocular tissues and are
overexpressed in the diabetic retina. An-
giotensin II (AT) binds and activates two
primary receptors, AT1-R and AT2-R. In
adulthumans,activationoftheAT1-Rex-
pressed in endothelial cells and pericytes
dominates the pathological states (40).
AT1-R activation by AT produced by the
retina stimulates several pathways in-
volved in the pathogenesis of diabetic ret-
inopathy such as inﬂammation, oxidative
stress, cell proliferation, pericyte migra-
tion, remodelling of extracellular matrix
by increasing matrix metalloproteinases,
angiogenesis, and ﬁbrosis (40). The RAS
is upregulated concomitant with hy-
poxia-induced retinal angiogenesis and is
linked to AT-mediated induction of in-
ﬂammatory mediators and growth fac-
tors,includingVEGFandplatelet-derived
growthfactor(40,41).Inaddition,AT1-R
activation by AT promotes leukostasis
and neurodegeneration (40), two key el-
ementsinthepathogenesisofdiabeticret-
inopathy. Most of these pathogenic
actions are inhibited or attenuated by
pharmacological blockade of the RAS ei-
ther at levels of ACE or the AT receptors
and are accompanied by downregulation
of VEGF and VEGFR-2 (40). Recently,
Kim et al. (42) have shown that perindo-
pril (an ACE inhibitor) attenuates VEGF-
mediated BRB breakdown in rats with
streptozotocin-induced diabetes. In addi-
tion,itisalsoworthyofmentionthatcan-
desartan inhibited retinal accumulation
of the advanced glycation end product
pentosidine in spontaneously diabetic
Torii rats (43). Apart from reducing mi-
crovascular disease, there is growing evi-
dence pointing to neuroprotection as a
relevant mechanism involved in the ben-
eﬁcial effects of angiotensin receptor
blockersindiabeticretinopathy(44–46).
On these experimental bases, it
wouldbereasonabletopostulatethatRAS
blockade can promote higher beneﬁcial
effects in diabetic retinopathy than other
antihypertensive agents. However, stud-
ies in type 2 diabetic patients with hyper-
tension suggest that ACE inhibitors and
angiotensin receptor blockers are not su-
perior in preventing or arresting diabetic
retinopathy to other drugs equally effec-
tive in reducing blood pressure such as
the -blocker atenolol (47) or calcium
channel blocker nisoldipine (48). These
prospective randomized studies suggest
that lowering blood pressure seems to be
much more important than the potential
effect of RAS blockade in the diabetic eye.
However, the question concerning the
potentialeffectofRASblockersinnormo-
tensive diabetic patients remains to be
elucidated. In the EURODIAB Controlled
Trial of Lisinopril in Insulin-Dependent
Diabetes Mellitus (EUCLID), it was re-
ported that in normotensive patients
(blood pressure 140/90 mmHg), either
normoalbuminutic (85% of patients) or
microalbuminuric, lisinopril (an ACE in-
hibitor) had no effect in reducing the in-
cidence of diabetic retinopathy but
decreased its progression by two or more
grades and decreased the progression to
PDR (49). However, these results have
beencriticizedbecausetheplacebogroup
had signiﬁcantly higher levels of mean
A1C than the treatment group. In fact,
after adjusting for A1C, the observed dif-
ferences in progression by two levels and
progression to PDR disappear and only
theprogressionbyonelevelremainedsig-
niﬁcant. Other limiting factors of this
study were the short period of follow-up
(2 years) and the fact that diabetic reti-
nopathy was not the primary end point of
the study. Therefore, although the
EUCLID study supported the idea of an
additional beneﬁt of ACE inhibitors on
diabetic retinopathy progression, it was
underpowered for the eye-related out-
comemeasuresused.Furthermore,inthe
normotensive type 2 diabetic patients of
the Appropriate Blood Pressure Control
in Diabetes (ABC) study, Schrier et al.
(50) showed that intensive blood pres-
sure control decreased the progression of
diabetic retinopathy. However, the re-
sults were the same whether enalapril or
nisoldipine was used as the initial antihy-
pertensive agent. Therefore, the speciﬁc
antihypertensive agent again appears to
belessimportantthantheachievementof
the lower blood pressure values.
The Diabetic Retinopathy Candesar-
tan Trials (DIRECT) program was there-
fore designed to answer the question of
whether the blockade of RAS with AT1-R
blockercandesartancouldpreventthein-
cidenceandprogressionofretinopathyin
type1andtype2diabetesindependentof
lowering blood pressure (11,12). This
program consisted of three randomized
double-blindplacebo-controlledparallel-
group studies: 1) a primary prevention
study involving 1,241 type 1 diabetic pa-
tients without diabetic retinopathy
(DIRECT-Prevent 1), 2) a secondary pre-
vention study involving 1,905 type 1 di-
abetic patients with diabetic retinopathy
(DIRECT-Protect 1), and 3) a secondary
prevention study involving 1,905 type 2
diabetic patients with diabetic retinopa-
thy (DIRECT-Protect 2). In each trial, pa-
tients were randomized to receive
candesartan (16–32 mg/day) or placebo
and the median follow-up was 4.7 years.
Patients with type 1 diabetes were eligible
for inclusion if they were normoalbumin-
uric and normotensive (blood pressure
130/85 mmHg). For patients with type
2diabetes,theinclusioncriteriawerenor-
moalbuminuria and either normal blood
pressure without antihypertensive ther-
apy or blood pressure 160/90 mmHg
during treatment. The primary end point
was the incidence of diabetic retinopathy
in the primary prevention study and pro-
gression of diabetic retinopathy in the
secondary prevention studies. In the
DIRECT-Prevent 1 study, a nonsigniﬁ-
cant reduction (18% relative risk reduc-
tion;P0.051)intheriskofincidenceof
diabetic retinopathy was observed. How-
ever, in a post hoc analysis in which the
primary end point was changed from a
two-step increase to at least a three-step
increase in the ETDRS scale, a signiﬁcant
difference was detected (35% relative risk
reduction; P  0.003). This beneﬁcial ef-
fect was attenuated but still signiﬁcant af-
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diabetes, A1C, and systolic blood pres-
sure (26% relative risk reduction; P 
0.046) (11). In DIRECT-Protect 1, an
identical progression of diabetic retinop-
athy was found in the placebo and in the
candesartan groups, thus suggesting that
candesartan is not effective in preventing
diabetic retinopathy progression (11).
DIRECT-Protect 2 showed a nonsignif-
icant reduction in the progression of di-
abetic retinopathy (13% relative risk;
P  0.20). However, a signiﬁcant in-
crease in diabetic retinopathy regres-
sion was observed (34%, P  0.009),
this effect being more evident in pa-
tients with mild retinopathy (12). Thus,
although the prespeciﬁed primary end
point was not reached in the DIRECT
program,dataanalysissuggestsanover-
all beneﬁcial effect of candesartan in di-
abetic retinopathy.
The DIRECT results should be com-
pared with the Action in Diabetes and
Vascular Disease (ADVANCE) study,
which included 11,140 type 2 diabetic
patients (51). In this study, patients ran-
domizedtointensiveglucosecontrolwith
glicazide (modiﬁed release), as well as
other drugs required to achieve A1C
6.5% and an ACE inhibitor–diuretic
combination (perindopril-indapamide),
presented the same 4-year incidence or
progression of diabetic retinopathy as the
placebo group. These results suggest the
possibility that candesartan but not ACE
inhibitors might have beneﬁcial effects in
diabetic retinopathy. However, it should
be noted that unlike DIRECT, ADVANCE
did not use standardized retinal photog-
raphy and there was a lower rate of pro-
gression of diabetic retinopathy, thus
limiting the power of the study to detect
any moderate effects of intervention on
microvascular eye disease.
INTRAVITREAL ANTI-VEGF
AGENTS— VEGF has been identiﬁed
as having a major role in the genesis of
diabetic retinopathy, with increased lev-
els in animals with experimental diabetes
and in the vitreous of patients with dia-
betic retinopathy. Intravitreal VEGF ad-
ministration in experimental animals
duplicates many features of diabetic reti-
nopathy. Thus, agents that attenuate
VEGF action are very attractive because
they are able to reduce permeability and
neovascularization,thehallmarksofDME
and PDR, respectively (4,52).
In general, systemically administered
drugs reach the retinochoroidal tissue via
blood circulation. However, because the
BRB limits the inﬂux of drugs into the ret-
ina, large amounts of the drug must be
administered to maintain therapeutic
concentrations. Regarding anti-VEGF
agents, this would lead to systemic inhi-
bition of angiogenesis, which could com-
promise critical vascular response to
ischemic events in diabetic patients with
cardiovascular, cerebrovascular, or pe-
ripheral vascular disease. Moreover, hy-
pertension and proteinuria (two
surrogatemarkersofsystemicVEGFinhi-
bition) as well as the impairment of
wound healing are other potential conse-
quences of blocking VEGF and would be
particularly worrying to the diabetic pop-
ulation(14).Bycontrast,thelocaladmin-
istration of anti-VEGF agents into the eye
by means of intravitreal injections would
avoid systemic adverse effects. However,
this is invasive and a skilled specialist is
required.Inaddition,inordertomaintain
effective levels, frequently repeated injec-
tions would be necessary, thus increasing
local complications such as endoph-
thalmitis, vitreous hemorrhage, retinal
detachment, and traumatic cataract. Fur-
thermore, although the eye is thought of
as a closed and self-contained system,
anti-VEGF drugs injected into the vitre-
ous cavity pass into systemic circulation
to varying degrees and could potentially
cause the systemic adverse effects men-
tionedpreviously(14,52).Atpresentfour
anti-VEGF agents are available: pe-
gaptamib sodium (macugen; Pﬁzer),
ranibizumab (lucentis; Genentech/
Novartis), bevacizumab (avastin; Genen-
tech), and aﬂibercept (Regeneron
Pharmaceuticals/sanoﬁ-aventis).
Pegaptanib is a PEGylated (i.e., con-
jugated to polyethylene glycol) neutraliz-
ing RNA aptamer with an extremely high
afﬁnity for isoform 165 of VEGF
(VEGF165), which is the isoform that par-
ticipates in pathological but not physio-
logical neovascularization (53). Aptamers
are modiﬁed nucleotides composed of
single-stranded nucleic acids that adopt a
speciﬁc three-dimensional conforma-
tion, allowing them to bind with high
speciﬁcity and afﬁnity to molecular tar-
gets in a manner similar to that of
monoclonal antibodies. An important
feature of aptamers is that they do not
exhibit immunogenicity. Pegaptamib
was approved by the U.S. Food and
Drug Administration (FDA) for treat-
ment of exudative (wet or neovascular)
age-related macular disease (AMD) in
December 2004.
Ranibimizumab is a full-length
monoclonal antibody directed against
VEGF.Incontrasttopegaptamib,ranimi-
zumab inhibits the biological activity of
allisoformsofhumanVEGFandcouldbe
immunogenic.TheFDAapprovedranibi-
zumab for wet AMD in June 2006.
Bevacizumab is an anti-VEGF agent
similar to ranibizumab and was approved
bytheFDAinFebruary2004forthetreat-
ment of disseminated colorectal cancer
but not licensed for intraocular use. Nev-
ertheless, intravitreal injection of bevaci-
zumab has become a current off-label
treatment by ophthalmologists for neo-
vascular AMD because although it seems
to be as effective as pegaptamib or rani-
mizumab, it is much cheaper.
Aﬂibercept, also known as a VEGF
Trap-Eye because of its ability to block all
sixVEGFproteins(VEGF-AtoVEGF-Eas
well as placental growth factor), is a fu-
sionproteincomprisedofsegmentsofthe
extracellulardomainsofhumanVEGFre-
ceptors 1 (VEGFR1) and 2 (VEGFR2)
fused to the constant region (Fc) of hu-
man IgG. Aﬁlbercept is currently being
used in clinical trials for both exudative
AMD and DME. Aﬂibercept has a higher
binding afﬁnity than other anti-VEGF
agents. This higher binding afﬁnity trans-
lates into greater activity at lower biolog-
ical levels and, consequently, a longer
duration of action.
The results of prospective clinical tri-
als using pegaptanib and ranibizumab in
patients with AMD have been very im-
pressiveandhaveledtothedesignofspe-
ciﬁc trials for DME and PDR. At present,
only a prospective double-blind multi-
center dose-ranging controlled trial has
beenreportedindiabeticpatients(54).In
this study 172 patients with DME were
included, and the patients randomized to
receive repeated intravitreal pegaptamib
showed better visual outcomes (P 
0.03), were more likely to show a reduc-
tion in retinal thickness (P  0.02), and
needed less additional focal laser (P 
0.04) at follow-up (36 weeks) than pa-
tients who received intravitreal sham in-
jections.Retrospectivedataanalysisofthe
eyes of 16 patients with PDR also showed
regression of neovascularization (55).
Uncontrolled studies using ranibi-
zumab and bevacizumab have also found
a rapid regression of retinal neovascular-
ization, improvement of visual acuity,
and decrease of retinal thickness in DME,
even in nonresponders to conventional
treatment(14,56).However,theresponse
totreatmentofDMEbyVEGFblockadeis
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variability. This is in distinct contrast to
the rapid response of those with both iris
andretinalneovascularizationinPDRand
of those with choroidal neovasculariza-
tioninwetAMD(57).Interestingly,when
the outcomes of intravitreal bevacizumab
treatment of DME were compared with
those of intravitreal cortisone (triamcino-
lone acetonide), better outcomes in terms
ofreductionoffovealthicknessandvisual
results were found with triamcinolone
(58).TheextenttowhichVEGFblockade
is beneﬁcial for DME is currently being
investigated in prospective clinical trials.
Apart from their potential as isolated
treatments for PDR and DME, intravitreal
anti-VEGF agents, in particular bevaci-
zumab, have been shown to be useful in
increasing the short-term response to
panretinal photocoagulation in high-risk
PDR and also seem to be efﬁcacious and
safe as an adjuvant treatment to vitrec-
tomy in severe PDR or vitreous hemor-
rhage (56). This is because intravitreal
anti-VEGF agents reduce active neovas-
cularization and vitreous hemorrhage,
thus allowing a safe and efﬁcient panreti-
nalphotocoagulationorparsplanavitrec-
tomy to be performed while minimizing
the risk of complications. Aﬂibercept has
been recently tested in an exploratory
study performed in ﬁve patients with
DME (59). In this study, using a single
intravitreal injection, Trap-Eye was well
toleratedandpreliminaryevidenceofbio-
activity was detected. Taken together,
thesepromisingresultspresentanewsce-
nario in the management of diabetic reti-
nopathy. Nevertheless, larger studies
investigating not only the effectiveness
but also the systemic adverse effects of
theseagentsinthediabeticpopulationare
still needed.
It is possible that a drug with more
extensive and nonspeciﬁc anti-VEGF ac-
tivity, such as pan-VEGF inhibitors
(ranibizumab, bevacizumab, and aﬂiber-
cept), could be more effective than a drug
such as pegaptamib that selectively tar-
gets VEGF165. In this regard, pegaptamib
is substantially less effective than ranibi-
zumab in AMD treatment. By contrast,
given that VEGF165 plays an essential role
inpathologicalbutnotphysiologicalneo-
vascularization, pegaptanib could be the
best option for avoiding systemic adverse
effects in diabetic patients. In addition,
long-term intravitreous injections of pan-
VEGFinhibitorscouldleadtoretinalneu-
rodegeneration and an increased risk of
circulationdisturbancesinthechoriocap-
illaris (60). However, the theoretical ad-
vantage of selective blocking of VEGF165
by pegaptamib in terms of both systemic
and local side effects remains to be dem-
onstrated in head-to-head clinical trials.
CONCLUDING REMARKS
AND FUTURE RESEARCH — Tight
controlofbloodglucoselevelsandhyper-
tension remains the key element for pre-
venting or arresting diabetic retinopathy.
However,twodrugs(fenoﬁbrateandcan-
desartan), originally not designed for
treatment of diabetic retinopathy, have
become new adjuncts in its management.
Theinformationdrawnfromclinicaltrials
indicates that in normotensive diabetic
patients, candesartan reduces the inci-
dence of diabetic retinopathy in those
with type 1 diabetes and favors diabetic
retinopathy regression only in type 2 dia-
betic patients with mild retinopathy. By
contrast,fenoﬁbrate,whichhasonlybeen
tested in type 2 diabetes, has no effect on
the incidence of diabetic retinopathy.
However,itreducestheprogressionofex-
istingdiabeticretinopathy,thuslessening
the need for laser treatment in both DME
and PDR, and this beneﬁcial effect is
unrelated to changes in serum lipids.
Therefore, it would be reasonable to rec-
ommend candesartan for type 1 diabetic
patients(withorwithouthypertension)at
high risk to develop diabetic retinopathy
and for type 2 diabetic patients with mild
retinopathy,whereasfenoﬁbrateseemsto
be a good option for type 2 diabetic pa-
tients (with or without dyslipemia) with a
wide range of diabetic retinopathy stages
(from mild to severe nonproliferative di-
abetic retinopathy). In addition, the ben-
eﬁt on diabetic retinopathy shown by
fenoﬁbrate and candesartan should be
considered an extra value when treating
dyslipemia and hypertension in diabetic
patients. Nevertheless, the mechanisms
by which candesartan and, in particular,
fenoﬁbrate exert their reported beneﬁts
need to be elucidated before these drugs
can be launched (alone or in combina-
tion) as new tools in the management of
diabetic retinopathy. Another question
needing speciﬁc research is whether such
treatments could be administered topi-
cally and directly into the eye in order
to increase the beneﬁts in diabetic
retinopathy.
In advanced stages of diabetic reti-
nopathy, intravitreal delivery of anti-
VEGF agents are currently used by many
ophthalmologists despite the lack of
phase3studiessupportingtheireffective-
nessandsafety.Thisisduetothesuccess-
ful results obtained in wet AMD and the
promising preliminary data in diabetic
retinopathy.Intravitrealinjectionpermits
antiangiogenic drugs to effectively reach
theretinaandtheoreticallyovercomesthe
problem of the systemic blockade of an-
giogenesis. However, this is an invasive
procedure that can have complications
such as endophthalmitis and retinal de-
tachment and could even have deleteri-
ous effects for the remaining healthy
retina. This is especially important in di-
abetic patients for whom long-term ad-
ministration is expected. Apart from local
side effects, anti-VEGF agents could also
produce systemic complications because
of their capacity to pass into systemic cir-
culation. The effectiveness and safety of
intravitreal anti-VEGF agents are being
evaluated in several clinical trials. Mean-
while, in order to minimize systemic ad-
verse effects, it seems reasonable to avoid
long-term treatment with anti-VEGF
agents for patients with hypertension,
proteinuria, renal failure, cardiovascular
disease, and foot lesions with wound
healing impairment.
A future scenario will involve using a
combination of anti-VEGF agents and la-
ser photocoagulation or combining anti-
angiogenic agents aimed at different steps
of angiogenic cascade. This would proba-
bly be more successful than single-
molecule–speciﬁc approaches, would
permitadecreaseinthefrequencyofdos-
ing,andwouldreduceadverseeffects.Al-
though it is premature at this stage to
advocate such maneuvers, these aspects
are certainly worth pursuing in future
studies because they may suggest attrac-
tive new strategies for improving the
treatment of diabetic retinopathy. How-
ever, it should be emphasized that, at
present, the milestones in diabetic reti-
nopathytreatmentaretheoptimizationof
blood glucose levels, lowering of blood
pressure, and regular fundoscopic
screening.
In summary fenoﬁbrate, candesartan,
and anti-VEGF agents are now in the ar-
mamentarium for diabetic retinopathy
treatment. Ophthalmologists and physi-
cians treating diabetic patients should be
aware of the potential usefulness of these
drugs and work together not only in fu-
ture research but also in establishing clin-
ical guidelines that will include these
newermedicaltreatmentsfordiabeticret-
inopathy. Only such coordinated action,
as well as competent strategies targeting
prevention, will be effective in reducing
Medical treatment for diabetic retinopathy
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outcome of this devastating complication
of diabetes.
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